Science
Mechanism of Action
R-CLOSTRIDIUM HISTOLYTICUM COLLAGENASE H HEXAPEPTIDE-40 employs a synergistic dual mechanism of action. The collagenase component, comprising AUX-I and AUX-II enzymes from *Clostridium histolyticum*, functions as a precise proteinase. It specifically hydrolyzes collagen in its native triple helical conformation, facilitating the targeted breakdown and subsequent removal of old or damaged collagen deposits. Concurrently, the hexapeptide-40 is designed to mimic natural collagen fragments within the skin, thereby stimulating the skin's intrinsic repair mechanisms, promoting cellular regeneration, strengthening dermal architecture, and contributing to a visible reduction in wrinkle depth.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
The Formula
Formulation
Stability
The collagenase enzyme maintains optimal stability and activity at a neutral pH of 7.4, requiring a calcium ion concentration of 0.3-0.5 mM for sustained efficacy over at least 5 hours at 37°C. Solutions are stable for several months when stored at -20°C; however, repeated freeze-thaw cycles must be strictly avoided to preserve ingredient integrity. Zinc ions are critical for activity, though often adequately bound from purification, negating the need for additional zinc unless chelators are present in the formulation.
Conflicts
- Chelating agents (e.g., Ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 8-hydroxyquinoline)
- Reducing agents (e.g., Beta-mercaptoethanol, Glutathione, Thioglycolic acid)
- Substances that significantly alter pH from neutrality
Safety
Safety Profile
Collagenase Clostridium Histolyticum (CCH) is FDA-approved as an injectable drug (e.g., Xiaflex, Qwo) for specific medical indications such as Dupuytren's contracture, Peyronie's disease, and moderate to severe cellulite. Clinical trials for these injectable applications generally indicate good tolerability, with most adverse events being localized injection-site reactions like bruising, pain, and edema. No quantifiable systemic CCH levels were detected in human plasma following a single subcutaneous dose. However, it is imperative to note that this approval is for a medical drug application, and specific Cosmetic Ingredient Review (CIR) or SCCS assessments for the topical cosmetic ingredient R-CLOSTRIDIUM HISTOLYTICUM COLLAGENASE H HEXAPEPTIDE-40 have not been conducted.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While presenting a theoretically compelling dual mechanism for targeted collagen remodeling and skin regeneration, the absence of specific cosmetic safety and efficacy data warrants further comprehensive research before definitive recommendation for topical skincare formulations.
Related
Similar Ingredients
Finding similar ingredients…